When was Dewpoint Therapeutics founded?

Dewpoint Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Dewpoint Therapeutics located?

Dewpoint Therapeutics is headquartered in Boston, United States. It is registered at 451 D Street, Suite 104 Boston, MA 02210.

How many employees does Dewpoint Therapeutics have?

As of Jun 30, 2026, the latest employee count at Dewpoint Therapeutics is 56.

Is Dewpoint Therapeutics a funded company?

Dewpoint Therapeutics is a funded company, having raised a total of $364M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 30, 2019.

When was the latest funding round of Dewpoint Therapeutics?

Dewpoint Therapeutics' latest funding was a $***** Series D round on Sep 09, 2025, with participation from 0 investor.

Where does Dewpoint Therapeutics rank among its competitors?

Dewpoint Therapeutics ranks 9th amongst 1948 active competitors, of which 452 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Dewpoint Therapeutics?

Dewpoint Therapeutics' top competitors include Synthego, Antheia and Transcenta. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Dewpoint Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Dewpoint Therapeutics is a series D company based in Boston (United States), founded in 2018 by Richard Young. It operates as a Developer of small molecule based therapeutics. Dewpoint Therapeutics has raised $364M in funding from investors like Polaris Partners, Arch Venture Partners and Maverick Ventures. The company has 1948 active competitors, including 452 funded and 336 that have exited. Its top competitors include companies like Synthego, Antheia and Transcenta.

Company Details

Dewpoint Therapeutics is involved in development of small molecules based therapeutics. The company offers condensate biology to create dynamic, liquid compartments in cells for the treatment of neurodegeneration, cancer, and other diseases.

Website: dewpointx.com
Social
Email ID: *****@dewpointx.com, *****@dewpointx.com
Phone Number: +1 **********
Registered Address: 451 D Street, Suite 104 Boston, MA 02210

Key Metrics

Founded Year

2018

Location

Boston, United States

Stage

Series D

Total Funding

$364M in 4 rounds

Latest Funding Round

Series D, Sep 09, 2025, $*****

Investors

Polaris Partners & 17 more

Ranked

9^th among 1948 active competitors

Employee Count

56 as on Jun 30, 2026

Similar Companies

Synthego & 2658 more

View Dewpoint Therapeutics' full profile

Dewpoint Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dewpoint Therapeutics, Inc. CIN: 83-1952330 , United States, Active	Sep 17, 2018	-	41 (As on Dec 31, 2020)	-
Dewpoint Therapeutics GmbH CIN: HRB40295 , Germany, Active	Aug 09, 2020	-	41 (As on Dec 31, 2020)

Dewpoint Therapeutics has raised a total funding of $364M over 4 rounds. Its first funding round was on Jan 30, 2019. Dewpoint Therapeutics has 18 institutional investors.

Here is the list of recent funding rounds of Dewpoint Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 09, 2025	3130854	Series D	1117078	6517194	1337304	6131712
Feb 03, 2022	8271659	Series C	4196124	9757079	3576683	General Catalyst & 10 more
Sep 29, 2020	4115665	Series B	2646936	9632793	Maverick Ventures	Bellco Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Dewpoint Therapeutics's funding rounds and investors

The founders of Dewpoint Therapeutics is Richard Young.

Here are the details of Dewpoint Therapeutics' key team members:

Richard Young: Co-Founder of Dewpoint Therapeutics. They serve on the board of 1 company.

View details of Dewpoint Therapeutics's Founder profiles and Board Members

Dewpoint Therapeutics' employee count trend

Dewpoint Therapeutics has 56 employees as of Jun 26. Here is Dewpoint Therapeutics's employee count trend over the years:

Employee count trend for Dewpoint Therapeutics

Uncover Dewpoint Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dewpoint Therapeutics include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Dewpoint Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, New Enterprise Associates ... & 14 others	64/100
6th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 13 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Timefolio Capital, Mubadala & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Dewpoint Therapeutics's competitors? Click here to see the top ones

Dewpoint Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Dewpoint Therapeutics's geography:

Free

US Fintech Quarter Funding Report

Edition: Quarter 1, 2026 (41 Pages)

View all reports related to Dewpoint Therapeutics

Media has covered Dewpoint Therapeutics for a total of 4 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.